Effect of cyclophosphamide on cytokines in patients with primary Sjögren’s syndrome-associated interstitial lung disease in South China

被引：0

作者：

Lihua Zhang

Hanyou Mo

Mengya Zhu

Lifang Wang

机构：

[1] The Affiliated Hospital of Guilin Medical College,Department of Clinical Immunology and Rheumatology

来源：

Rheumatology International | 2013年 / 33卷

关键词：

Cyclophosphamide; Sjögren’s syndrome; Tumornecrosis factor-alpha; Transforming growth factor betal; Matrix metalloproteinase-9;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

The objective of the study is to investigate the mechanisms of cyclophosphamide sequential therapy for patient with primary Sjögren’s syndrome-associated interstitial lung disease (PSS-ILD). This was a retrospective review of 15 patients (2005–2008) with PSS-ILD who underwent cyclophosphamide sequential therapy. Peripheral blood and bronchoalveolar lavage (BALF) were obtained before and 3, 6, 12 and 24 months after the treatment. The TNF-α and TGF-β1 mRNA levels in peripheral blood were measured using reverse transcription polymerase chain reaction. Serum and BALF TNF-α, TGF-β1 and MMP-9 levels were measured using sandwich enzyme-linked immunosorbent assay. The average levels of serum TNF-α (0.39 ± 0.22) and TGF-β1 (0.31 ± 0.18) mRNA in patients with PSS-ILD were higher compared with that in patients with PSS without ILD. TNF-α level (0.23 ± 0.19) was significantly decreased 3 months after cyclophosphamide treatment (t = 2.533, p < 0.05), and TGF-β1 (0.31 ± 0.18) level markedly decreased after 6 months of treatment (t = 2.617, p < 0.05). The levels of serum TNF-α (11.2 ± 2.6) μg/L, TGF-β1 (72 ± 19) μg/L and MMP-9 (38 ± 9) μg/L in patients with PSS-ILD were higher than that in patients with PSS without ILD. TGF-β1 (36 ± 12) μg/L level decreased significantly after 3 months of treatment (t = 2.526, p < 0.05), and TNF-α level (7.1 ± 1.3) μg/L markedly decreased after 6 months of therapy (t = 2.578, p < 0.05). MMP-9 level (18 ± 4) μg/L decreased significantly after 12-month treatment (t = 2.329, p < 0.05). The levels of BALF TNF-α (17.1 ± 3.5) μg/L, TGF-β1 (36 ± 17) μg/L and MMP-9 (27 ± 10) μg/L in patients with PSS-ILD were higher than that in patients with PSS without ILD. TGF-β1 (21 ± 14) μg/L level decreased significantly after 3-month treatment, and TNF-α level (9.4 ± 1.7) μg/L was decreased after 6 months of cyclophosphamide treatment that may be associated with its inhabitation on production of TNF-α, TGF-β1 and MMP-9.

引用

页码：1403 / 1407

页数：4

共 29 条

[1]

Wills BC(2006)Epithelial origin of myofibroblasts during fibrosis in the lung Proc Am Thorac Soc 3 377-382

[2]

duBois RM(2004)The role of transforming growth factor beta in lung development and disease Chest 125 754-765

[3]

Borok Z(2005)Tumor necrosis factor-alpha overexpression in lung disease: a single cause behind a complex phenotype Am J Respir Crit Care Med 171 1363-1370

[4]

Bartram U(2004)Idiopathic pulmonary fibrosis: pathogenesis and therapeutic approaches Drugs 64 405-430

[5]

Speer CP(1998)Intravenous pulse cyclophosphamide in the treatment of interstitial lung disease due to collagen vascular diseases Arthr Rheum 41 1215-1220

[6]

Lundblad LK(2002)International multidisciplinary consensus classification of the idiopathic interstitial pneumonias Am J Respir Crit Care Med 165 277-304

[7]

Thompson-Figueroa J(2007)TGF-beta, Smad3 and the process of progressive fibrosis Biochem Soc Tram 35 661-664

[8]

Leclair T(2004)Matrix metalloproteinase 9(MMP-9) gene polymorphism and MMP-9 plasma levels in primary Sjogren’s syndrome Rheumatology (Oxford) 43 1476-1479

[9]

Selman M(2007)British thoracic society study on cryptogenie fibrosing alveolitis: response to treatment and survival Thorax 62 62-66

[10]

Thannickal VJ(2001)Steroids in idiopathic pulmonary fibrosis: a prospective assessment of adverse reactions, response to therapy, and survival Am J Med 110 278-282

← 1 2 3 →